PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and the next-generation HYDROS Robotic System, AI-powered, image-guided surgical robotic platforms used to deliver Aquablation therapy for the minimally invasive treatment of benign prostatic hyperplasia (BPH).
PROCEPT BioRobotics is publicly traded
IPO'd on September 15, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under PRCT.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2009
Employees
501–1,000
Total Funding
$329.65M
6 rounds
Total raised $329.65M across 6 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series G
Date
June 2021
Amount
$85M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| June 2021 | Series G | $85M | — | Fidelity |
| August 2020 | Series F | $77M | — | Not disclosed |
| February 2018 | Series E | $118M | — | Viking Global Investors |
Larry L. Wood
President and Chief Executive Officer
Kevin Waters
Executive Vice President, Chief Financial Officer
Sham Shiblaq
Executive Vice President, Chief Commercial Officer
Alaleh Nouri
Executive Vice President, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Stacey Porter
Chief People Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Teleflex
Medical device company that markets the UroLift System, a minimally invasive prostatic urethral lift implant for BPH.
Boston Scientific
Medical device company that markets the Rezum water vapor therapy system for BPH, acquired through its 2018 purchase of NxThera.
Olympus
Medical technology company offering endoscopic and laser-based devices used in BPH treatment, including HoLEP and ThuLEP procedures.
Yes, PROCEPT BioRobotics is publicly traded under the ticker symbol PRCT on the Nasdaq. The company went public in September 15, 2021.
PROCEPT BioRobotics trades under the ticker symbol PRCT on the Nasdaq. It began trading in September 15, 2021.
PROCEPT BioRobotics (PRCT on the Nasdaq) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker PRCT to place an order.
PROCEPT BioRobotics went public in September 15, 2021 via ipo. PROCEPT BioRobotics priced its upsized IPO on September 14, 2021 at $25.00 per share, with 6,556,000 shares offered for total gross proceeds of $163.9 million. Common stock began trading on the Nasdaq Global Market on September 15, 2021 under the ticker PRCT.
PROCEPT BioRobotics raised $329.65M across 6 disclosed funding rounds prior to its public listing.
PROCEPT BioRobotics is headquartered in Redwood City, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.